← Screener

CRLCharles River Laboratories

Health care · Research Services · NYSE

Compare with peers → Embed

FY2025 at a glance

Sales down 0.9%, free cash flow up to $518.5M

XBRL, from each 10-K

RevenueStatements ↓

$4.0B

from $4.0B in FY2024

FY2016FY2025

Net incomeStatements ↓

-$144.3M

from $22.2M in FY2024

FY2016FY2025

Free cash flowStatements ↓

$518.5M

from $501.6M in FY2024

FY2016FY2025

EPS (diluted)Statements ↓

$-2.91

from $0.20 in FY2024

FY2016FY2025

Operating marginStatements ↓

0.6%

from 5.6% in FY2024

FY2016FY2025

Total debtStatements ↓

$2.1B

from $2.2B in FY2024

FY2016FY2025

Price and key numbers

The latest figures

All key numbers (36, from the latest 10-K and 10-Q) From EDGAR

EPS (ttm)	0.92	Sales (ttm)	4.0B	Net income (ttm)	40.2M	Sales growth	-0.9%	EPS growth	n/m	Sales Q/Q	-2.2%
Free cash flow	399.6M	Gross margin	-	Oper. margin	4.0%	Net margin	1.0%	FCF margin	10.0%	ROE	1.2%
ROA	0.5%	R&D / sales	-	Dividend	-	Debt/Eq	0.76	Curr. ratio	1.41	Cash	200.4M
Op. cash flow (ttm)	622.4M	EBITDA	428.5M	EBITDA margin	10.7%	Net debt	2.2B	Quick ratio	1.13	Interest cover	0.24
Stock pay / sales	1.8%	Shares out.	47.9M	Shares Y/Y	-4.0%	Book / share	67.35	Cash / share	4.18	Sales / share	82.99
Asset turnover	0.53	Days sales out.	64	Sales 3Y CAGR	+0.3%	Sales 5Y CAGR	+6.5%	Employees	19,700	Sales / employee	202K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Changes in the numbers

FY2025 against FY2024

Operating margin narrowed to 0.6%5.6% → 0.6% · Operating income / revenue · 10-K ↗
Net income turned to a loss$22.2M → −$144.3M · Net income attributable to the company · 10-K ↗

What management wrote about it → · Every company →

CRL against Health care peers

Ten years, side by side → · All 60 →

CRLPeer median

Each side 0 to 100, ranked against every company we cover: relative position on reported figures, not a buy score. How

Every dot is one of the 60 companies, the better end on the right. Hover a dot for the company.

Sales growth

-0.9%57th of 60 · median +7.1%

Net margin

1.0%52nd of 60 · median 9.6%

Return on equity

1.2%49th of 54 · median 13.1%

Free cash flow margin

10.0%37th of 56 · median 15.5%

Debt / equity (less is better)

0.7635th of 49 · median 0.66

CRL and the 5 peers closest in revenue
Company	Revenue (ttm)	Sales growth	Gross margin	Net margin	ROE	FCF margin	Debt / equity
CRL Charles River Laboratories	$4.0B	-0.9%	-	1.0%	1.2%	10.0%	0.76
ILMN Illumina, Inc.	$4.5B	-0.7%	67.9%	19.7%	28.5%	23.3%	0.57
COO Cooper Companies	$4.2B	+5.1%	65.9%	13.5%	6.8%	16.0%	0.31
MTD Mettler Toledo	$4.2B	+4.0%	60.4%	22.2%	-	20.7%	-
ALGN Align Technology	$4.2B	+0.9%	69.1%	11.8%	11.4%	14.5%	-
VEEV Veeva Systems	$3.5B	+16.3%	75.0%	29.3%	13.7%	-	-

Profitability

0 of 3

!
Net margin below the peer median1.0% vs 9.6%
!
Return on equity below 15%1.2%
!
A profit in 9 of 10 years

Net margin, FY2016 to FY2025: 9.2% → -3.6%

Balance sheet

2 of 4

!
Interest covered less than 5 timesOperating income is 0.2× interest expense
✓
Debt smaller than equityDebt / equity 0.76 on the latest balance sheet (peer median 0.66)
✓
Current assets cover current liabilitiesCurrent ratio 1.41
!
Net debt over 3 years of free cash flow$2.2B net debt, 5.6 years

Debt / equity at each year end, FY2016 to FY2025: 1.41 → 0.68

What the debt is made of ↓

Cash and shareholders

2 of 2

✓
Free cash flow positive in every one of 10 years$518.5M last year
✓
Share count down over 5 years−2.1%

Free cash flow, FY2016 to FY2025: 261.6M → 518.5M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Debt

$2.1B of principal due, schedule of Dec 27, 2025

Repayment schedule →

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Revenue and net income, FY2016 to FY2025

Revenue 4.0B Net income -144.3M

From XBRL in each 10-K. Hover a bar for the line item and filing. Full financials →

Where the $4.0B of revenue came from

by product, year to Dec 27, 2025

Service $3.3B · 81%
Product $765.3M · 19%

From the segment tables in the 10-K XBRL. Revenue by segment, product and region →

Statements

Income statement, balance sheet and cash flow

XBRL, each 10-K and 10-Q

CRL's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Annual Quarterly

Revenue4.0B

Net income-144.3M

Free cash flow518.5M

EPS (diluted)-2.91

Diluted shares49.6M

The segments changed

10-K filed 2026-02-18

Compared with the 10-K of Feb 19, 2025: no longer reported: Research Models And Services.

When a company changes its segments, the years before are usually recast, so growth by segment is not comparable with what earlier 10-Ks showed. Found by comparing the segments with revenue in the last two 10-Ks (XBRL) and by the 10-K's own words, without AI.

Revenue by business segment

year to Dec 27, 2025

	Revenue	Share	vs year before
DSA	2.4B	59.8%	-2.0%
RMS	846.1M	21.1%	+2.0%
Manufacturing	766.4M	19.1%	-0.4%

10-K 0001100682-26-000022, segment and revenue notes (XBRL).

Revenue by product or service

year to Dec 27, 2025

	Revenue	Share	vs year before
Service	3.3B	80.9%	-1.6%
Product	765.3M	19.1%	+2.6%

10-K 0001100682-26-000022, segment and revenue notes (XBRL).

Revenue by region

year to Dec 27, 2025

	Revenue	Share	vs year before
U.S.	2.1B	53.3%	-4.4%
Europe	1.1B	27.5%	+2.3%
Canada	501.0M	12.5%	+3.9%
Asia Pacific	205.0M	5.1%	+4.1%
Other	64.9M	1.6%	+22.8%

10-K 0001100682-26-000022, segment and revenue notes (XBRL).

Income statement

From EDGAR

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	1.7B	1.9B	2.3B	2.6B	2.9B	3.5B	4.0B	4.1B	4.0B	4.0B
Cost of revenue	277.0M	289.7M	-	-	-	-	-	-	-	-
SG&A	364.7M	371.3M	443.9M	517.6M	528.9M	619.9M	665.1M	747.9M	751.0M	743.1M
Operating income	237.6M	288.3M	331.4M	351.2M	432.7M	589.9M	651.0M	617.3M	227.3M	25.2M
Interest expense	27.7M	29.8M	63.8M	60.9M	86.4M	73.9M	59.3M	136.7M	126.3M	107.0M
Pretax income	222.9M	297.0M	281.7M	304.1M	447.1M	480.7M	623.0M	581.3M	93.1M	-99.5M
Income tax	66.8M	171.4M	54.5M	50.0M	81.8M	81.9M	130.4M	100.9M	67.8M	42.7M
Net income	154.8M	123.4M	226.4M	252.0M	364.3M	391.0M	486.2M	474.6M	22.2M	-144.3M
EPS (diluted)	3.23	2.54	4.62	5.07	7.20	7.60	9.48	9.22	0.20	-2.91
Diluted shares	48.0M	48.6M	49.0M	49.7M	50.6M	51.4M	51.3M	51.5M	51.6M	49.6M
Depreciation & amortization	126.7M	131.2M	161.8M	198.1M	234.9M	265.5M	303.9M	314.1M	361.7M	403.3M
EBITDA	364.2M	419.4M	493.2M	549.2M	667.7M	855.4M	954.8M	931.4M	589.1M	428.5M
Operating margin	14.1%	15.5%	14.6%	13.4%	14.8%	16.7%	16.4%	14.9%	5.6%	0.6%
Net margin	9.2%	6.6%	10.0%	9.6%	12.5%	11.0%	12.2%	11.5%	0.5%	-3.6%
Revenue growth	-	+10.5%	+22.0%	+15.7%	+11.5%	+21.1%	+12.3%	+3.9%	-1.9%	-0.9%
EPS growth	-	-21.4%	+81.9%	+9.7%	+42.0%	+5.6%	+24.7%	-2.7%	-97.8%	-1555%

Balance sheet

From EDGAR

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash	117.6M	163.8M	195.4M	238.0M	228.4M	241.2M	233.9M	276.8M	194.6M	213.8M
Short-term investments	3.8M	28.5M	885K	941K	1.0M	1.1M	-	-	-	-
Receivables	364.1M	430.0M	472.2M	514.0M	617.7M	642.9M	752.4M	780.4M	720.9M	708.9M
Inventory	95.8M	115.0M	127.9M	160.7M	185.7M	199.1M	255.8M	380.3M	278.5M	299.1M
Current assets	656.8M	826.6M	897.8M	1.0B	1.2B	1.3B	1.4B	1.6B	1.4B	1.4B
Property & equipment	755.8M	782.0M	932.9M	1.0B	1.1B	1.3B	1.5B	1.6B	1.6B	1.7B
Goodwill	787.5M	804.9M	1.2B	1.5B	1.8B	2.7B	2.8B	3.1B	2.8B	2.8B
Total assets	2.7B	2.9B	3.9B	4.7B	5.5B	7.0B	7.6B	8.2B	7.5B	7.1B
Accounts payable	68.5M	77.8M	66.2M	111.5M	122.5M	198.1M	205.9M	168.9M	140.3M	148.8M
Current liabilities	429.6M	463.5M	558.2M	710.2M	839.8M	1.0B	1.1B	1.1B	994.1M	1.1B
Total debt	1.2B	1.1B	1.6B	1.9B	2.0B	2.7B	2.7B	2.7B	2.2B	2.1B
Total liabilities	1.9B	1.9B	2.5B	3.0B	3.3B	4.4B	4.6B	4.5B	4.0B	3.9B
Shareholders' equity	836.8M	1.0B	1.3B	1.6B	2.1B	2.5B	3.0B	3.6B	3.5B	3.2B
Retained earnings	165.3M	288.7M	42.1M	280.3M	625.4M	980.8M	1.4B	1.9B	1.8B	1.4B

Cash flow

From EDGAR

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Operating cash flow	316.9M	318.1M	441.1M	480.9M	546.6M	760.8M	619.6M	683.9M	734.6M	737.6M
Capital spending	55.3M	82.4M	140.1M	140.5M	166.6M	228.8M	324.7M	318.5M	233.0M	219.2M
Free cash flow	261.6M	235.6M	301.1M	340.4M	380.0M	532.0M	294.9M	365.4M	501.6M	518.5M
Stock-based pay (added back)	43.6M	44.0M	47.3M	57.3M	56.3M	71.5M	73.6M	72.0M	69.9M	71.1M
Buybacks	12.3M	106.9M	13.8M	18.1M	24.0M	40.7M	38.7M	24.2M	119.2M	360.7M
Acquisitions	648.5M	25.0M	824.9M	515.7M	418.6M	1.3B	283.4M	194.8M	5.5M	0
Debt raised	1.0B	236.9M	2.8B	3.4B	2.2B	7.0B	3.0B	776.4M	1.1B	1.2B
Investing cash flow	-692.7M	-72.6M	-955.0M	-681.5M	-601.5M	-1.4B	-607.9M	-563.2M	-245.1M	-209.3M
Financing cash flow	380.8M	-208.5M	558.1M	231.9M	47.2M	672.6M	-42.4M	-85.5M	-550.9M	-536.7M

Stock-based pay and leases

From EDGAR

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Stock-based pay (expense)	43.6M	44.0M	47.3M	57.3M	56.3M	71.5M	73.6M	72.0M	69.9M	71.1M
Stock-based pay / revenue	2.6%	2.4%	2.1%	2.2%	1.9%	2.0%	1.9%	1.7%	1.7%	1.8%
Operating lease cost	-	-	-	30.9M	33.0M	45.7M	59.7M	65.4M	71.1M	70.8M
Operating lease cash paid	-	-	-	27.2M	30.0M	42.6M	48.4M	60.2M	74.7M	78.7M
Finance lease principal paid	-	-	-	3.8M	4.3M	3.2M	2.3M	2.3M	2.9M	3.6M
Right-of-use assets	-	-	134.2M	140.1M	178.2M	292.9M	391.8M	394.0M	412.5M	361.4M
Operating lease liabilities	-	-	-	136.6M	180.3M	286.2M	436.3M	474.1M	537.9M	491.7M
Finance lease liabilities	-	-	-	30.5M	29.0M	27.2M	30.6M	28.6M	28.4M	27.9M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Next Peers in numbers →